S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
Log in

Mesa Laboratories Stock Forecast, Price & News

-1.68 (-0.57 %)
(As of 01/15/2021 12:00 AM ET)
Today's Range
Now: $295.33
50-Day Range
MA: $281.76
52-Week Range
Now: $295.33
Volume25,922 shs
Average Volume20,792 shs
Market Capitalization$1.51 billion
P/E RatioN/A
Dividend Yield0.22%
Mesa Laboratories, Inc. designs, manufactures, and markets quality control instruments and disposable products in the United States, Canada, Europe, and Japan. The company's Sterilization and Disinfection Control segment manufactures and markets biological indicators comprising spore strips, self-contained products, and culture media, as well as process challenge devices; and offers testing services. This segment also provides chemical and cleaning indicators that are used to assess the effectiveness of sterilization and cleaning processes. Its Instruments segment offers data loggers used in critical manufacturing, quality control, and validation applications; medical meters and calibration solutions used to test various parameters of the dialysis fluid, and the calibration and operation of the dialysis machine; gas flow calibration and air sampling equipment that are used for industrial hygiene assessments, calibration of gas metering equipment, and environmental air sampling; and torque testing systems used for measure bottle cap tightness. This segment's products are used in healthcare, pharmaceutical, medical device, food and beverage, industrial hygiene, and environmental air sampling industries. The company's Biopharmaceutical Development segment develops, manufactures, and commercializes automated solutions for protein analysis, which include analysis equipment, CDs, kits, and buffers; and peptide synthesizers to automate chemically synthesized peptides that are used in the creation of peptide therapies, biomaterials, cosmetics, and general research. Its Continuous Monitoring segment offers systems, which are used to monitor temperature, humidity, and differential pressure for use in hospitals, pharmaceutical and medical device manufacturers, blood banks, pharmacies, and laboratory environments. The company was founded in 1982 and is headquartered in Lakewood, Colorado.
Mesa Laboratories logo


Overall MarketRank

1.51 out of 5 stars

Medical Sector

351st out of 1,556 stocks

Process Control Instruments Industry

10th out of 23 stocks

Analyst Opinion: 1.0Community Rank: 2.6Dividend Strength: 1.7Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Process control instruments
Sub-IndustryElectronic Equipment & Instruments
Current SymbolNASDAQ:MLAB



Sales & Book Value

Annual Sales$117.69 million
Cash Flow$9.96 per share
Book Value$50.34 per share


Net Income$1.35 million


Market Cap$1.51 billion
Next Earnings Date2/8/2021 (Estimated)
OptionableNot Optionable
-1.68 (-0.57 %)
(As of 01/15/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MLAB News and Ratings via Email

Sign-up to receive the latest news and ratings for MLAB and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Mesa Laboratories (NASDAQ:MLAB) Frequently Asked Questions

How has Mesa Laboratories' stock price been impacted by Coronavirus?

Mesa Laboratories' stock was trading at $230.99 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, MLAB shares have increased by 27.9% and is now trading at $295.33.
View which stocks have been most impacted by COVID-19

Is Mesa Laboratories a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mesa Laboratories in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Mesa Laboratories stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MLAB, but not buy additional shares or sell existing shares.
View analyst ratings for Mesa Laboratories
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Mesa Laboratories?

Wall Street analysts have given Mesa Laboratories a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Mesa Laboratories wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Mesa Laboratories' next earnings date?

Mesa Laboratories is scheduled to release its next quarterly earnings announcement on Monday, February 8th 2021.
View our earnings forecast for Mesa Laboratories

How were Mesa Laboratories' earnings last quarter?

Mesa Laboratories, Inc. (NASDAQ:MLAB) released its earnings results on Thursday, November, 5th. The medical instruments supplier reported $1.53 earnings per share for the quarter, beating the consensus estimate of $0.86 by $0.67. The medical instruments supplier earned $31.86 million during the quarter, compared to the consensus estimate of $30.27 million. Mesa Laboratories had a negative net margin of 2.04% and a positive return on equity of 6.39%.
View Mesa Laboratories' earnings history

How often does Mesa Laboratories pay dividends? What is the dividend yield for Mesa Laboratories?

Mesa Laboratories announced a quarterly dividend on Tuesday, January 5th. Shareholders of record on Friday, February 26th will be paid a dividend of $0.16 per share on Monday, March 15th. This represents a $0.64 dividend on an annualized basis and a yield of 0.22%. The ex-dividend date is Thursday, February 25th.
View Mesa Laboratories' dividend history

Is Mesa Laboratories a good dividend stock?

Mesa Laboratories pays an annual dividend of $0.64 per share and currently has a dividend yield of 0.22%. Mesa Laboratories does not yet have a strock track record of dividend growth. The dividend payout ratio of Mesa Laboratories is 15.20%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Mesa Laboratories will have a dividend payout ratio of 10.29% next year. This indicates that Mesa Laboratories will be able to sustain or increase its dividend.
View Mesa Laboratories' dividend history.

What price target have analysts set for MLAB?

2 brokers have issued twelve-month price targets for Mesa Laboratories' shares. Their forecasts range from $260.00 to $287.00. On average, they anticipate Mesa Laboratories' stock price to reach $273.50 in the next year. This suggests that the stock has a possible downside of 7.4%.
View analysts' price targets for Mesa Laboratories
or view Wall Street analyst' top-rated stocks.

Who are some of Mesa Laboratories' key competitors?

What other stocks do shareholders of Mesa Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Mesa Laboratories investors own include NVIDIA (NVDA), Verizon Communications (VZ), Intel (INTC), Alibaba Group (BABA), Altria Group (MO), Micron Technology (MU), Exxon Mobil (XOM), AbbVie (ABBV), Advanced Micro Devices (AMD) and Becton, Dickinson and (BDX).

Who are Mesa Laboratories' key executives?

Mesa Laboratories' management team includes the following people:
  • Mr. Gary M. Owens, CEO, Pres & Director (Age 52, Pay $1.19M)
  • Mr. John V. Sakys, CFO, Chief Accounting Officer, Sec. & Treasurer (Age 51, Pay $596.4k)
  • Mr. Gregory T. DiNoia, Sr. VP of Commercial Operations (Age 55, Pay $491.16k)
  • Mr. Brian David Archbold, Sr. VP of Continuous Improvement (Age 55, Pay $423.68k)
  • Ms. Helene R. Leone, Gen. Counsel
  • Mr. Peter Jung, VP of Corp. Devel. & Strategy
  • Mr. Bryan T. Leo, Sr. VP of Operations
  • Mr. Garrett Krushefski, Sr. VP of Operations

What is Mesa Laboratories' stock symbol?

Mesa Laboratories trades on the NASDAQ under the ticker symbol "MLAB."

Who are Mesa Laboratories' major shareholders?

Mesa Laboratories' stock is owned by many different institutional and retail investors. Top institutional investors include State of Alaska Department of Revenue (0.07%). Company insiders that own Mesa Laboratories stock include Brian David Archbold, David M Kelly, Evan Guillemin, Gary M Owens, Gregory Dinoia, John Bradley Schmieder, John James Sullivan, John Sakys and Robert V Dwyer.
View institutional ownership trends for Mesa Laboratories

Which major investors are selling Mesa Laboratories stock?

MLAB stock was sold by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue. Company insiders that have sold Mesa Laboratories company stock in the last year include Brian David Archbold, David M Kelly, Evan Guillemin, Gary M Owens, Gregory Dinoia, John Bradley Schmieder, John James Sullivan, John Sakys, and Robert V Dwyer.
View insider buying and selling activity for Mesa Laboratories
or view top insider-selling stocks.

How do I buy shares of Mesa Laboratories?

Shares of MLAB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Mesa Laboratories' stock price today?

One share of MLAB stock can currently be purchased for approximately $295.33.

How big of a company is Mesa Laboratories?

Mesa Laboratories has a market capitalization of $1.51 billion and generates $117.69 million in revenue each year. The medical instruments supplier earns $1.35 million in net income (profit) each year or $4.21 on an earnings per share basis. Mesa Laboratories employs 460 workers across the globe.

What is Mesa Laboratories' official website?

The official website for Mesa Laboratories is www.mesalabs.com.

How can I contact Mesa Laboratories?

Mesa Laboratories' mailing address is 12100 W 6TH AVE, LAKEWOOD CO, 80228. The medical instruments supplier can be reached via phone at 303-987-8000 or via email at [email protected]

This page was last updated on 1/17/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.